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Enhanced antibiotic distribution strategies
and the potential impact of facial cleanliness
and environmental improvements for the
sustained control of trachoma: a modelling
study
Amy Pinsent1*, Matthew J. Burton2 and Manoj Gambhir1
Abstract
Background: Despite some success in controlling trachoma with repeated mass drug administration (MDA), some
hyperendemic regions are not responding as fast as anticipated. Available data suggests that individuals with
higher bacterial infection loads are less likely to resolve infection following a single dose of treatment, and thus remain
a source of re-emergent infection following treatment. We assessed the potential impact of a new double-dose
antibiotic distribution strategy in addition to enhanced facial cleanliness (F) and environmental improvements (E).
Methods: Using a within-community mathematical model of trachoma transmission we assessed the impact of a new
double-dose antibiotic distribution strategy given 2 weeks apart, with and without enhanced F&E. We compared the
annual double-dose strategy to single-dose annual MDA treatment in hyper-, meso- and hypoendemic settings, and to
biannual MDA at 6-monthly intervals in hyperendemic communities.
Results: The findings from our mathematical model suggest that implementing the new double-dose strategy for
5 years or less was predicted to control infection more successfully than annual or 6-monthly treatment. Infection was
controlled more readily if treatment was combined with enhanced F&E. The results appeared robust to variation in a
number of key epidemiological parameters. To have long-term impact on transmission, enhanced F&E is essential for
high transmission settings.
Conclusion: Our current findings are based on simualtion modelling only, due to lack of epidemilogical data, however
they do suggest that the annual double-dose treatment strategy is encouraging for trachoma control. In high
transmission settings, both MDA and enhanced F&E are needed for sustained control.
Keywords: Mathematical modelling, Trachoma, Mass drug administration, GET 2020, Control, Elimination
Background
Trachoma remains the most common infectious cause
of blindness worldwide. It is estimated that 84 million
people, mostly young children, have active disease, and
1.2 million people are blind from trachoma [1]. Blind-
ness occurs as a result of repeated infection of the ocular
surface with the bacterium Chlamydia trachomatis. The
infection results in chronic, recurrent conjunctival in-
flammation (active trachoma), which then progresses to
scarring [2]. This scarring leads to in-turning of the
eyelashes, known as trachomatous trichiasis (TT), which
traumatises the eye surface leading to corneal opacification
and blindness [2].
To prevent sight loss from trachoma, effective long-
term control of C. trachomatis infection and transmission
is required [2]. The World Health Organization (WHO)
aims to eliminate trachoma as a public health problem by
2020. To help achieve this, the Alliance for the Global
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Elimination of Trachoma by the year 2020 (GET 2020)
was formed. The Alliance has two major elimination
targets, the first of which is to reduce the prevalence of
trachomatous inflammation, follicular (TF) in children
aged 1–9 years old to < 5 % in all endemic regions by
2020. To help reach this goal, the WHO recommends
the use of the SAFE strategy: surgery for trichiasis, anti-
biotics to treat infection, facial cleanliness and environ-
mental improvements to suppress transmission [2].
Programmatic success is evaluated through follow-up
surveys assessing prevalence of TF in 1–9-year-olds,
following several annual antibiotic treatment rounds.
The current antibiotic of choice is oral azithromycin,
which is distributed to entire endemic districts meeting
the intervention criteria. The WHO recommends that
treatment is repeated annually for an initial 3–5-year
period, depending on the baseline disease prevalence [3].
Unfortunately, particularly in areas with a high baseline
prevalence, the response to treatment at the community
level has been relatively disappointing. In some areas
which have been studied in detail, such as Kongwa,
Tanzania [4], and Gurage, Ethiopia [5], more than seven
rounds of treatment have been deployed; however,
prevalence of active disease has not dropped below the
target level of < 5 % in children aged 1–9 years to eliminate
trachoma as a public health problem. This is supported by
findings from a recent study, in which the authors sug-
gested that countries should prepare for extended antibiotic
timelines [6]. As the target date to eliminate trachoma as a
public health problem by 2020 fast approaches, there is a
pressing need to identify alternative, more effective anti-
biotic distribution strategies for highly endemic regions.
Individuals with the highest ocular chlamydial loads
are most commonly young children, under 10 years of age
[7]. Available data suggest that individuals with higher
bacterial infection loads are less likely to resolve infection
upon treatment than children with a lower starting load.
Therefore, children with the highest bacterial loads pre-
treatment can remain a source for re-emergent infection
in the community [8]. Additionally, re-emergence of dis-
ease clusters have been reported around households of
children identified as having high bacterial loads [9, 10].
Furthermore, simply increasing the dose of azithromycin
for those with severe active trachoma (as a surrogate
marker for higher infection loads) was not found to be
more effective than a standard dose in resolving
infection [9]. Similarly, treatment of individuals with
severe active trachoma with two standard antibiotic
doses given on consecutive days was also not found to be
more effective than the standard single dose [11].
However, it is possible that the second dose applied
in this trial on the second day did not have additional
benefit, as it was administered when an individual
probably still had a high bacterial load [11].
Therefore, in this study we suggest the implementation
of an alternative double-dose antibiotic distribution
strategy, where two doses of antibiotic are administered
2 weeks apart from one another. The rationale for this
approach is that the probability of resolving infection
following treatment is related to the load. The available
data suggest that while some high-load infections do
fully resolve following a single dose of treatment, a pro-
portion of these high-load infections do not; however,
they do transition into a lower-load category [8]. Here,
the first dose of antibiotic treatment acts to reduce an
individual’s bacterial load. Individuals are then re-
treated 2 weeks after the first dose. Those that are still
infected after the first treatment are likely to be in a
lower-load state, and as such, they have a higher probabil-
ity of fully resolving their infection following the second
antibiotic dose.
Treatment of infection with antibiotics represents only
one arm of the SAFE strategy. Indeed, a recent analysis
suggested that particularly for highly endemic regions,
repeated annual single-dose mass drug administration
(MDA) alone is insufficient to eliminate infection, without
lasting environmental improvements [6]. The quantitative
impact of non-pharmaceutical interventions (NPIs) on
trachoma transmission remains unclear. One recent study
attempted to quantify the impact of facial cleanliness (F)
and environmental improvements (E) in helping to reduce
transmission and the odds of acquiring infection [12]. The
authors suggested that the impact of improved sanitation
and hygiene in helping to reduce trachoma transmission is
currently underestimated and that it can help to reduce
the odds of acquiring infection [12]. However, the mecha-
nisms of transmission remain poorly defined, and there
are few randomised control trials in this area to support
or quantify the role of F&E on trachoma.
Here, we propose a development of the existing F&E
interventions, which we refer to as ‘enhanced F&E’. In
this trial scenario, enhanced F&E would be developed
through intensive observational studies, which document
human behaviour, its determinants and the hygiene prac-
tices adopted by individuals. This focused ethnographic
approach will thus document in detail key behaviours and
possible transmission routes relevant to trachoma trans-
mission. Through this, targeted F&E interventions will be
developed in partnership with the communities to gener-
ate promotional activities to prevent these pathways oc-
curring. It is this specific targeting of interventions and
promotional activity informed by ethnographic research
that defines enhanced F&E.
Previous mathematical modelling studies have sug-
gested that in areas of high transmission intensity at
least two rounds of single-dose antibiotic treatment at
6-monthly intervals may be needed to help control in-
fection [5, 13, 14]. However, one clinical trial in high
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prevalence communities reported that despite biannual
treatment for 3 years infection re-emerged [5]. The lo-
gistics and cost of distributing treatment at 6-monthly
intervals requires considerable resources. If the second
dose is given in quick succession there are likely to be
some savings in cost relative to giving MDA at 6-
monthly intervals; for example, less overall preparation
and management costs, it would only be necessary to
sensitise and mobilise the community once a year, and
there may also be some transport cost savings if the
distribution team is still in the same area.
Here, we explore the potential community-level im-
pact of the double-dose antibiotic distribution strategy
administered on an annual basis to help reduce trans-
mission of the pathogen and burden of disease within
the community. We examine the projected impact of re-
ductions in transmission that may occur as a result of
the introduction of enhanced F&E interventions, as de-
fined previously. We assess our findings across a range
of key parameters, including: frequency of treatment,
coverage of treatment, differential treatment efficacy and
a range of reductions in the transmission rate.
Methods
Model structure
The mathematical model developed represents ocular in-
fection events with C. trachomatis within a community.
The model is an extension of a susceptible, infected, sus-
ceptible (SIS) transmission model. We include two exten-
sions to this framework: firstly, the addition of a short
latent period; and secondly, a compartment that considers
individuals who present with active disease but do not test
PCR positive. This four-state structure is analogous to that
used by Grassly et al. [15]. Immunity to re-infection with
trachoma is short term; therefore, individuals can be re-
peatedly infected throughout their lifetime. To account for
this we follow the ‘ladder of infection’ model struc-
ture initially presented by Gambhir et al. [16, 17]. A
flow diagram of the infection process is presented in
Fig. 1. We follow all individuals from their first infec-
tion onwards; however, after 100 infections, improved
immunity with re-infection plateaus, and an individual’s
first ten infections are considered high load (sensitivity
Fig. 1 A flow diagram of the SIAIAD trachoma infection transmission
model. Individuals begin as susceptible to their first infection (S),
become infected at a rate λ, progress to the incubating class (I) and
leave at a rate γi, which does not depend on the previous number of
infections they have had. They progress into the infected with active
disease compartment (AI) and leave at a rate σi, which does depend on
the previous number of infections experienced. They lastly progress
into the active disease compartment (AD), where they are not
infectious but still have identifiable active disease, individuals recover
from active disease and become susceptible to infection again at a rate
ζi, which depends on the number of infections experienced
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of the results to these assumptions are presented in
Additional file 1). In the absence of any empirical
data we assumed that repeated infection did not alter an
individual’s incubation period, or their susceptibility
to re-infection. Further detail on the modelling methods is
provided in Additional file 1.
We assumed a hyperendemic community had a PCR
prevalence of infection > 20 %, a mesoendemic community
had ≤ 20 % and a hypoendemic community had < 10 %.
On a person-by-person basis, the relationship between the
prevalence of infection and TF is not directly linear;
however, at the population level this relationship is ap-
proximately linear.
Modelling different intervention scenarios
We considered four different treatment scenarios. For
hyperendemic communities, we modelled five annual
rounds of MDA, with follow-up extending for 1 year
after the final treatment. For the meso- and hypoen-
demic communities, we modelled three annual rounds
of MDA for each setting, with follow-up extending for
3 years after the third treatment. A differential treatment
efficacy for individuals with high and low bacterial loads
was assumed for all intervention scenarios. Treatment
efficacy was consistent across all rounds of treatment.
Scenario one: single-dose annual MDA. Scenario two:
the new alternative treatment regime of a double-dose of
annual MDA, given in quick succession 2 weeks apart.
Scenario three: single-dose annual MDA, with a once-off
instantaneous drop in the transmission rate parameter β
at the time of the first MDA treatment in year one. Since
β is the product of the transmission probability and the
contact rate between individuals, we consider this in-
stantaneous drop in β to model the impact of the intro-
duction of enhanced F&E within the community. This
instantaneous drop in β occurred only once in the first
year at the first round of treatment, but was sustained
for the 6-year period. Further reductions in β after this
first round of treatment were not modelled. Scenario
four: double-dose annual MDA and a once-off instant-
aneous drop in β at time of first MDA treatment in year
one (as described for scenario three). Again, here the
instantaneous drop in β represents the introduction of
enhanced F&E.
For the hyperendemic community, we also compared
the new double-dose treatment strategy to biannual
treatment at 6-monthly intervals.
Sensitivity analysis
Given the limited availability of data to parameterise
achievable reductions in the probability of transmission
through enhanced F&E, we explored a range of reduc-
tions in β. We assessed a percentage reduction in β from
0 % to 50 %. This did not directly impact an individual’s
bacterial load, but assumed that for any given bacterial
load level the probability of infection transmitted to a
susceptible individual in the community was lower fol-
lowing the implementation of enhanced F&E. For the
baseline analysis, we assumed an instantaneous reduc-
tion in β at the first treatment time point. However, it is
possible that even with a highly targeted F&E approach
interventions will not be accessed by all members of the
community equally, or at the same rate. We therefore
also considered a non-instantaneous reduction in β. In-
stead, we assumed an exponential reduction in β through-
out the intervention period, where, at each treatment time
point, β was also reduced by a small amount. Thus, the
cumulative reduction in β across the 3- or 5-year interven-
tion period remained the same as when the instantaneous
drop was considered, but at any given point in time prior
to the last round of MDA the value of β considering a
non-instantaneous drop would be higher than when the
instantaneous drop was assumed.
Estimates of the efficacy of azithromycin are variable
and can depend on the host’s bacterial load [8, 10]. There-
fore, we explored a range of plausible treatment efficacy
values. For those classified as having high bacterial loads
(high loaders) efficacy of treatment was assumed to range
between 40 % and 75 %. For those assumed to have low
bacterial loads (low loaders) treatment efficacy was as-
sumed to range between 70 % and 90 % (Additional file 1:
Table S1). The level of treatment coverage achieved is
likely to vary between settings, thus we assessed the
impact of each intervention scenario under different
coverage levels of 60–95 % (Additional file 1: Table S1).
We also assessed how our findings vary according to the
assumptions about when immunity to infection plateaus
and the number of infections that are high-load infections
(Additional file 1).
Lastly, our baseline model assumed that individuals in
the active disease state were immune to re-infection. We
performed a final sensitivity analysis to this assumption
and assumed individuals in the active disease state had a
50 % probability of being re-infected; results are presented
in Additional file 1.
Results
MDA alone
For a hyperendemic community with intervention sce-
nario two, infection and disease prevalence were reduced
to less than 10 % following the first year of treatment
(Fig. 2c, d), while with scenario one, prevalence was only
reduced to 20 % and rebounded within 1 year. Across
the five rounds we observed no long-term trends of an
overall decline in prevalence within the hyperendemic
community with a single annual dose (Fig. 2a, b), while
with the double-dose treatment we saw year-on-year
gains and the prevalence of disease was driven below
Pinsent et al. BMC Medicine  (2016) 14:71 Page 4 of 10
Fig. 2 Prevalence of infection and active disease in 0–9-year-olds when comparing single-dose annual MDA to double-dose annual MDA
(conducted 2 weeks apart) within a hyperendemic community for 5 years. We assumed 80 % coverage, and 65 % and 85 % efficacy of the
antibiotic for high and low bacterial loaders, respectively. Scenario 1: a prevalence of infection and b active disease with single-dose annual
MDA, with a 0 % decline in β. Scenario 2: c prevalence of infection and d active disease with double-dose annual MDA applied 2 weeks apart,
with a 0 % decline in β. Scenario 3: e prevalence of infection and f active disease with single-dose annual MDA. Scenario 4: g prevalence of
infection and h active disease with double-dose annual MDA applied 2 weeks apart. While also modelling an instantaneous drop in β, we
present a range of reductions in β. Different coloured lines represent different percentage declines in the value of β, ranging from 0–50 %.
Grey dashed line indicates 5 % prevalence, where < 5 % prevalence of active disease is the GET 2020 target level
Fig. 3 Prevalence of infection and active disease in 0–9-year olds when comparing single-dose annual MDA to double-dose annual MDA
(conducted 2 weeks apart) within a mesoendemic community for 3 years. We assumed 80 % coverage, and 65 % and 85 % efficacy of the
antibiotic for high and low bacterial loaders, respectively. Scenario 1: a prevalence of infection and b active disease with single-dose annual
MDA, with a 0 % decline in β. Scenario 2: c prevalence of infection and d active disease with double-dose annual MDA applied 2 weeks apart,
with a 0 % decline in β. Scenario 3: e prevalence of infection and f active disease with single-dose annual MDA. Scenario 4: g prevalence of
infection and h active disease with double-dose annual MDA applied 2 weeks apart. While also modelling an instantaneous drop in β, we
present a range of reductions in β. Different coloured lines represent different percentage declines in the value of β, ranging from 0–50 %.
Grey dashed line indicates 5 % prevalence, where < 5 % prevalence of active disease is the GET 2020 target level
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5 % following ten rounds of treatment. However, when
treatment ceased in both scenarios infection re-emerged
(Fig. 2a–d).
The MDA-induced prevalence decline in a mesoen-
demic community (Fig. 3a–d) was much larger than the
hyperendemic setting. Within 1 year of treatment, preva-
lence of infection was reduced to 5 % in scenario two,
while with scenario one it was reduced to 10 % (Fig. 3a,
c). Following cessation of treatment re-emergence of in-
fection was observed in scenario one (Fig. 3a, b), but not
scenario two (Fig. 3c, d).
After the first year of treatment with a single-dose
MDA, in a hypoendemic setting the prevalence of active
disease was not reduced to 5 % (Fig. 4a). While for sce-
nario two, after the first year of treatment prevalence of
active disease dropped to the target level of < 5 % and
remained so 3 years after treatment ceased (Fig. 4d).
MDA and transmission reduction through enhanced F&E
Transmission reduction in combination with MDA had
a larger impact on prevalence of infection and active dis-
ease in the hyperendemic community, in comparison to
MDA alone. For scenario three, at least 30 % transmission
reduction was required in addition to MDA (Fig. 2e, f ).
While in scenario four (Fig. 2g, h), a reduction of greater
than 10 % was sufficient to eliminate infection.
For the mesoendemic community, a 20 % decrease in
transmission produced a comparable level of final preva-
lence across the 6-year period with scenarios three and
four (Fig. 3e–h). With a 20 % reduction in transmission
in both scenarios, no re-emergence of infection was ob-
served (Fig. 3e–h). However, with scenario four, it may
be possible to eliminate infection within 2 years.
MDA and transmission reduction measures resulted in
large reductions in prevalence (Fig. 4e–h) in the hypoen-
demic setting. When β was reduced by at least 10 %, in-
fection was successfully eliminated under both MDA
distribution strategies, although infection was eliminated
more quickly from the community under scenario four
(Fig. 4e–h).
Biannual treatment at 6-monthly intervals vs two doses
2 weeks apart annually for a hyperendemic community
A more dramatic reduction in the prevalence of infection
and active disease was projected to be achieved with the
annual double-dose treatment strategy (scenario two) in
comparison to single-dose treatment at 6-monthly inter-
vals (Additional file 1: Figure S3). After 2 years of treat-
ment, prevalence of infection was reduced to 5 % for
scenario two, and this reduction in prevalence was not
achieved until 4 years after treatment was applied at
6-monthly intervals (Additional file 1: Figure S3). With an
instantaneous drop in the transmission rate of 10 %, infec-
tion was eliminated within the community after six rounds
of treatment with scenario four (Additional file 1: Figure
S3g); however, it required ten rounds with 6-monthly
treatment (Additional file 1: Figure S3e). Although, in both
scenarios infection re-emerged in the community if
Fig. 4 Prevalence of infection and active disease in 0–9-year olds when comparing single-dose annual MDA to double-dose annual MDA
(conducted 2 weeks apart) within a hypoendemic community for 3 years. We assumed 80 % coverage, and 65 % and 85 % efficacy of the
antibiotic for high and low bacterial loaders, respectively. Scenario one: a prevalence of infection and b active disease with single-dose annual
MDA, with a 0 % decline in β. Scenario two: c prevalence of infection and d active disease with double-dose annual MDA applied 2 weeks
apart, with a 0 % decline in β. Scenario three: e prevalence of infection and f active disease with one annual round of MDA. Scenario four:
g prevalence of infection and h active disease with double-dose annual MDA applied 2 weeks apart. While also modelling an instantaneous
drop in β, we present a range of reductions in β. Different coloured lines represent different percentage declines in the value of β, ranging from
0–50 %. Grey dashed line indicates 5 % prevalence, where < 5 % prevalence of active disease is the GET 2020 target level
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transmission was reduced by only 10 % (Additional file
1: Figure S3e–h).
Sensitivity analysis of the variation in coverage level
Across all transmission settings, as coverage and efficacy
reduced, the effect of all interventions was reduced. For
the hyperendemic community, if coverage was 60 %
neither antibiotic distribution strategy was sufficient to
control transmission and very high levels of transmission
reduction were required to eliminate infection (Additional
file 1: Figure S7–S9a–h). If coverage was increased to 70 %,
MDA alone was not sufficient to maintain infection control
in the hyperendemic community (Additional file 1: Figure
S10a–d). However, if coverage was increased to 95 %, a
steady decline in transmission was observed for all settings
and scenarios (Additional file 1: Figure S13–S15a–h). Al-
though, single-dose annual MDA showed limited impact
on transmission reduction in the absence of enhanced F&E,
particularly for hyperendemic communities.
Sensitivity analysis of the variation in antibiotic efficacy
Assuming a baseline level of coverage (80 %), as efficacy
of treatment reduced, the impact of MDA alone was also
reduced. At the lowest assumed efficacy of 40 % and
70 % for high and low bacterial loaders, respectively,
MDA alone had no long-term impact in any transmission
setting, and enhanced F&E was also needed to reduce
transmission (Additional file 1: Figure S16, S18, S20a–d).
However, under all scenarios the percentage reduction in
transmission through enhanced F&E required to control
transmission was lower with the proposed double-dose
strategy (Additional file 1: Figure S16, S18, S20e–h). As
the assumed efficacy of treatment increased, the success
of each intervention to reduce transmission improved
(Additional file 1: Figure S17, S19, S21a–h). However,
single-dose annual MDA alone was not sufficient to
control infection within the hyperendemic community,
and signs of re-emergence were apparent with the
double-dose strategy, in the absence of enhanced F&E
(Additional file 1: Figure S17).
Discussion
This study explored the projected effectiveness of differ-
ent antibiotic distribution strategies and levels of trans-
mission reduction on prevalence of infection and disease
in three different transmission settings, with the ultimate
aim of achieving the GET 2020 goal of reducing preva-
lence of TF in 1–9-year olds to < 5 %. It has previously
been demonstrated that the single-dose efficacy of azi-
thromycin treatment is not 100 %, particularly for those
with high bacterial loads [8, 10]. In the proposed
double-dose strategy, in cases where the infection does
not resolve, the first dose of antibiotic treatment reduces
an individual’s bacterial load, thus when they are re-
treated 2 weeks after the first dose, they have a higher
probability of resolving their infection following the sec-
ond dose. The implementation of this new strategy may
also help to increase the overall level of coverage achieved
across the two rounds, due to increased awareness, along
with catching individuals who may have missed the first
round of treatment. Although the number of antibiotic
doses required initially would be higher than when single-
round annual MDA is implemented, it is likely that the
total number of doses required for long-term control
would be fewer under the double-dose strategy as the
treatment programme would need to run for a shorter
time period.
To date, very few clinical studies have explicitly moni-
tored the impact of water, sanitation and hygiene (WASH)
or F&E on human behaviours; nor have they attempted to
quantify the possible impact of these interventions on
trachoma transmission within a clinical trails setting. Fur-
ther to this, these interventions have, to our knowledge,
not been previously assessed in the trachoma mathemat-
ical modelling literature. A key feature of the proposed
clinical trial is the enhanced F&E component. This com-
ponent seeks to draw ethnographic information on human
behaviours and practices to identify key routes of trach-
oma transmission within the community, facilitating the
formulation and development of highly specific and tar-
geted F&E interventions, which aim to directly reduce
trachoma transmission within the community. This will
for the first time allow estimates of highly targeted trans-
mission reduction measures for trachoma to be made.
We acknowledge that particularly for single-dose an-
nual MDA, the rates of infection rebound in the model
following treatment are generally higher than those ob-
served in the field [5, 18, 19]. However, high variance in
the number of cases reported following several rounds
of MDA is cited [18]. Furthermore, many antibiotic
treatment studies may have an F&E component, which
is not always explicitly monitored or quantified. There-
fore, we may expect an underlying degree of transmis-
sion reduction in these trials as well. As such, we may
expect findings from trials to look like the simulations
which model MDA with a small amount of transmission
reduction. Indeed, we see that the output from these
simulations show a much slower rebound effect.
We found that the GET 2020 goal of reducing preva-
lence of TF in children aged 1–9 years old to < 5 % may be
achievable with the interventions explored for a number
of transmission settings; however, monitoring will be
needed (and is recommended) to check that the preva-
lence remains below the elimination threshold, as our re-
sults suggest that in the absence of transmission reduction
interventions, infection may re-emerge. This observation
is supported by MDA clinical trial data [5, 18, 19]. One re-
cent theoretical modelling study suggested that if a
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community experienced 10 annual rounds of MDA and
rapid transmission reduction, shifts in population immun-
ity may be observed resulting in short-term increases in
R0 [20]. However, the modelling results presented here
suggest that with a smaller number of annual rounds of
MDA and transmission reduction through F&E it is pos-
sible to eliminate infection in all transmission settings.
For hyperendemic communities, the new double-dose
treatment regime may have a large impact on reducing
prevalence of infection, in comparison to single-dose an-
nual MDA. With a reduction of greater than 10 % in the
transmission parameter β through enhanced F&E, it may
be possible to control infection in hyperendemic com-
munities. The annual double-dose strategy was projected
to reduce prevalence of infection and disease more
quickly than biannual treatment at 6-monthly intervals.
However, as coverage and treatment efficacy reduced,
the projected effect of impact was also reduced. For ex-
ample, in the hyperendemic community, if coverage was
only 60 %, neither strategy in the absence of enhanced
F&E was sufficient to lower infection. This reinforces
the importance of attaining high levels of treatment
coverage to successfully control infection.
For hypo- and mesoendemic settings, the double-dose
distribution strategy was projected to provide an advan-
tage in helping to achieve the GET 2020 goal of redu-
cing the prevalence of active disease in 1–9-year olds.
The double-dose strategy reduced prevalence of infec-
tion more quickly in comparison to annual MDA, sug-
gesting that it may help to maintain a lower prevalence
of infection and active disease for longer periods. How-
ever, when efficacy of treatment and coverage level re-
duced, infection may be more likely to remerge.
Our study has a number of limitations. Firstly, we have
assessed the impact of interventions using a deterministic
mathematical model, which at high levels of transmission
intensity is reasonable. However, as transmission reduces
our model does not allow for the stochastic fade-out of
infection that may occur at low levels of prevalence and
transmission [21–23]. As such, we may have overesti-
mated the effort required to control infection at lower
levels of transmission intensity. Equally, re-emergence of
infection at very low transmission intensity may only be
an artefact of the deterministic model structure used here.
However, it is also important to consider that stochastic
re-emergence of infection within communities may occur.
Secondly, the quantitative impact of enhanced F&E re-
mains poorly understood; therefore, we have modelled
this effect through direct reductions in the transmission
rate parameter β. However, these interventions may act
through indirect means not explicitly accounted for in
the model. We do not know what these levels of trans-
mission reduction would correspond to in terms of
F&E control measures, nor do we know whether F&E
would be equally accessed by all members of the popu-
lation, though this seems a reasonable assumption for a
model. Additionally, the reduction in transmission may
not be instantaneous, but more gradual as hygiene and
sanitation conditions improve over time. However, sen-
sitivity analysis to this assumption suggested that it had
relatively little impact in the meso- and hypoendemic
settings (Additional file 1: Figure S35–S36). For hyper-
endemic communities, year-on-year reductions in in-
fection prevalence were slightly lower when β declined
more gradually over the 5-year period. However, as the
total level of transmission reduction in the community
achieved was the same in both situations, the results at
the end of the intervention period were the same. Here,
10–20 % reduction in transmission was sufficient to
eliminate infection with the double-dose treatment
strategy (Fig. 2 and Additional file 1: Figure S34).
Thirdly, while we have assessed the impact of our dif-
ferent intervention scenarios across a range of coverage
levels, it is possible that coverage may vary between
years of intervention implementation—this may impact
long-term trends in prevalence. Fourthly, as with many
modelling studies we have made a number of simplifying
assumptions, including assuming treatment efficacy was
the same for all individuals who were low loader and
those who were high. In reality, it is likely that efficacy
between all individuals will vary to some extent. How-
ever, capturing the heterogeneity in response to treat-
ment through high and low bacterial loads is one further
step in the development of biologically plausible models.
Further to this, we have assumed the primary mecha-
nisms underlying the re-emergence of infection within
the community are due to the failure of one antibiotic
dose to fully clear infection in those who have high bac-
terial loads; however, the picture is likely to be more
complex. We have assumed that individuals are missed
from treatment at random, though there may be small
groups of people or households who are systematically
not treated, resulting in continuous transmission within
these groups. However, ongoing transmission within
the household or the community is to some extent
accounted for in the re-emergence of infection within
the community under certain scenarios.
In addition, for a given level of treatment efficacy we
have assumed that for low loaders infection is fully cleared.
However, the microbial cure rate with azithromycin for
urogenital chlamydia is estimated to be 97–98 % [24]. This
‘latent chlamydia’ is believed to not be susceptible to treat-
ment, and is reported to be the reason behind the imperfect
cure rate for urogenital chlamydia. This observation may
also extend to ocular chlamydia, but to our knowledge, data
to support this in the ocular context remains limited. How-
ever, if there is a background level of latent chlamydia in
the community that is untreatable, the rate of infection
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re-bound within MDA-treated communities may be higher
than currently modelled here. The ability of individuals
with latent chlamydial infection to act as a reservoir source
of trachoma infection within the community remains
unknown and warrants further investigation.
We have assumed that individuals with active disease
are immune to re-infection, although a small amount of
clinical data has suggested that this might not be true.
However, very limited quantifiable information is available
to parameterise this. Nevertheless, sensitivity analysis to this
assumption suggested that an increase in the susceptibility
to re-infection in the AD state could lead to a larger impact
of the modelled interventions for both the single- and
double-dose treatment regimens across all transmission
settings (Additional file 1: Figure S37–S39). Lastly, we
have assumed that immunity to infection is acquired
exponentially, and high bacterial loads fall after the first
ten infections. However, immunity to infection may take a
different functional form, and it may require more or less
infections to qualify as a high or low bacterial loader. A re-
cent study in Kongwa, Tanzania, suggested that bacterial
load prior to MDA was not predictive of continued in-
fection in individuals following MDA [25]. However,
the authors acknowledge that this is not consistent with
their previous findings, and that the calculation of in-
fection load between the two studies limits their ana-
lysis [25]. We feel that two published studies, which
present conflicting results, do not provide sufficient
evidence to refute the hypothesis evaluated in this art-
icle. Moreover, there is also support in the urogenital
literature to suggest that organism load may be associ-
ated with treatment failure [26–28], highlighting that
the role of bacterial load and its association with treat-
ment failure is, at this point, not clear-cut.
Conclusions
Despite a number of limitations, we have assessed the
impact of our findings across a number of key assump-
tions, including assumptions relating to the variation in
the number of infections that are high load and when
immunity plateaus. Our results demonstrate the possible
impact the new antibiotic distribution strategy may have
in helping to reduce infection and disease, particularly in
high prevalence communities to help achieve the GET
2020 goal of eliminating trachoma as a public health
problem, and for some regions may help accelerate the
timeline to elimination. However, in high transmission
settings, MDA alone without sustained transmission
reduction through enhanced F&E is likely to lead to
re-emergence of infection within the community. The
logistics of treating twice within a short time period
means that fewer resources would be required than if
treatment was conducted at 6-monthly intervals. Therefore,
the projected impact this alternative antibiotic distribution
strategy and transmission reduction measures may have
provides a clear rationale for this strategy to be tested in a
clinical trials setting. It would be expected that the trial
would take a minimum of 3 years, with first reporting at
year one.
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